PTGS2 and malignant colon neoplasm: EGCG when applied to colon cancer cells, inhibited cyclooxygenase-2 (COX-2) and activated AMP-activated protein kinase (AMPK) accompanied by a decrease in vascular endothelial growth factor (VEGF) and Glut-1 levels [60,78].